Cyclerion Therapeutics Inc
CYCN1.690USD
-0.170-9.14%
Cierre 11/04, 16:00（ET）Cotizaciones retrasadas 15 min
5.20MCap. mercado
PérdidaP/E TTM
Más Datos de Cyclerion Therapeutics Inc Compañía
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Información de Cyclerion Therapeutics Inc
Símbolo de cotizaciónCYCN
Nombre de la empresaCyclerion Therapeutics Inc
Fecha de salida a bolsaMar 18, 2019
Director ejecutivoDr. Regina M. Graul, Ph.D.
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalMar 18
Dirección301 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Teléfono16176217722
Sitio Webhttps://www.cyclerion.com/
Símbolo de cotizaciónCYCN
Fecha de salida a bolsaMar 18, 2019
Director ejecutivoDr. Regina M. Graul, Ph.D.
Ejecutivos de Cyclerion Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mar., 2 de sep
Actualizado: mar., 2 de sep
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Otro
65.68%
Accionistas
Accionistas
Proporción
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Otro
65.68%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
22.05%
Corporation
9.43%
Investment Advisor
5.69%
Investment Advisor/Hedge Fund
5.63%
Hedge Fund
0.08%
Research Firm
0.03%
Otro
57.09%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
33
381.61K
11.43%
-552.00K
2025Q2
47
1.50M
44.80%
-242.81K
2025Q1
64
1.40M
44.62%
-170.60K
2024Q4
68
1.21M
44.74%
-507.00K
2024Q3
71
1.75M
64.88%
-8.65K
2024Q2
75
1.75M
64.62%
-27.65K
2024Q1
84
1.73M
66.48%
-9.21K
2023Q4
93
1.67M
68.18%
-15.51K
2023Q3
103
1.45M
60.44%
-312.49K
2023Q2
122
1.38M
57.36%
-283.95K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
Tyndall Management, LLC
155.19K
4.65%
-9.59K
-5.82%
Jun 30, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Fecha
Tipo
Relación
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
